Novavax Covid-19 vaccine updated for XBB.1.5 variant


Novavax has become the next company to have an updated version of its Covid-19 vaccine approved in the US.

The Food and Drug Administration (FDA) amended the emergency use authorisation (EUA) of the Novavax Covid-19 Vaccine, Adjuvanted, for use in individuals 12 years of age and older to include the 2023-2024 formula.

Individuals 12 years of age and older previously vaccinated with a Covid-19 vaccine (and who have not already been vaccinated with a recently updated mRNA Covid-19 vaccine) are eligible to receive one dose and unvaccinated individuals receive two doses.

The updated vaccine addresses currently circulating variants to provide better protection against serious consequences of Covid-19, including hospitalisation and death.

Consistent with the totality of the evidence and input from the FDA’s expert advisors, the Novavax Covid-19 Vaccine, Adjuvanted, a monovalent vaccine, has been updated to include the spike protein from the SARS-CoV-2 omicron variant lineage XBB.1.5 (2023-2024 formula).

This authorisation follows the FDA’s recent approvals and authorisations of updated mRNA Covid-19 vaccines for 2023-2024 manufactured by ModernaTX and Pfizer.

“The Covid-19 vaccines have saved countless lives and have prevented serious outcomes of Covid-19 caused by the SARS-CoV-2 virus,” said Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research. “Today’s authorisation provides an additional Covid-19 vaccine option that meets the FDA’s standards for safety, effectiveness and manufacturing quality needed to support emergency use authorisation.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free